

ASX Announcement

Imugene appoints Dr Ron Weitzman as Interim Chief Medical Officer

Sydney, Australia, 18 July 2023: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce the appointment of Dr Ron Weitzman as the Company's Interim Chief Medical Officer.

Dr Weitzman brings to Imugene over two decades of global experience in the biopharmaceutical industry, with expertise in the therapeutic areas of solid-tumour and hematologic malignancies. He has an extensive record in creating and executing clinical development plans, directing Phase I - III clinical trials, and preparing US and EU regulatory submissions.

Prior to joining Imugene, Dr Weitzman held leadership roles at various global biopharmaceutical companies, including Tango Therapeutics, Exelixis, Genentech, and Novartis.

Most recently as Chief Medical Officer at Tango Therapeutics, Dr Weitzman oversaw development of multiple oncology drugs, including three Investigational New Drug (IND) submissions, while leading the clinical and clinical operations teams.

Prior to his tenure at Tango Therapeutics, Dr Weitzman served as Vice President of Clinical Development at Exelixis for almost seven years. His role saw him take on the overall responsibility for the strategy and execution of the clinical plan for cabozantinib, a drug therapy for prostate cancer. This role included numerous visits to FDA and EMEA, authorship of regulatory documents, active participation in industry partnership meetings, and presentations to investors and the Exelixis Board of Directors.

California-based Dr Weitzman graduated from the University of Western Ontario, Canada, and is Board Certified by the American Board of Internal Medicine in Medical



Oncology. He is an active member of several professional societies including the College of Physicians and Surgeons of Ontario, the American College of Physicians, and the American Society of Clinical Oncology.

"It's a pleasure to welcome Dr Weitzman to our leadership team," said Imugene Managing Director and CEO Leslie Chong. "His wealth of experience in drug development will prove invaluable as we continue to advance our pipeline. His strong regulatory and oncology drug development background and demonstrated success in overseeing complex projects will also be an excellent asset that will complement our already world-class team."

Dr Weitzman replaces the departing Dr Giovanni Selvaggi in the role of Interim Chief Medical Officer. Imugene's board and management thanks Dr Selvaggi for his service to Imugene.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter and Instagram @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited
View us on YouTube @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to



treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer